Blog

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the

The Auto-Tires-Trucks group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Michelin (MGDDY) is a stock that can certainly grab

For those looking to find strong Retail-Wholesale stocks, it is prudent to search for companies in the group that are outperforming their peers. Figs (FIGS) is a stock that can certainly grab the

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The research service

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop

Investors interested in Consumer Discretionary stocks should always be looking to find the best-performing companies in the group. Callaway Golf (CALY) is a stock that can certainly grab the

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different

DENTSPLY SIRONA Inc. XRAY reported fourth-quarter 2025 adjusted earnings per share (EPS) of 27 cents, up 3.8% year over year. The bottom line missed the Zacks Consensus Estimate by 3.6%.

GAAP loss

Cracker Barrel Old Country Store, Inc. CBRL is scheduled to report second-quarter fiscal 2026 results on March 4, 2026.

CBRL’s earnings beat the Zacks Consensus Estimate in three of the trailing

Cactus, Inc. WHD reported fourth-quarter 2025 adjusted earnings of 65 cents per share, which beat the Zacks Consensus Estimate of 58 cents. The bottom line declined from the year-ago quarter’s

Xenon Pharmaceuticals XENE reported a loss of $1.31 per share for the fourth quarter of 2025, wider than the Zacks Consensus Estimate of a loss of $1.20. The company had incurred a loss of 84 cents

SoundHound AI, Inc. SOUN reported fourth-quarter 2025 results, wherein earnings came in line with the Zacks Consensus Estimate, but revenues surpassed the same.

SoundHound AI is gaining momentum as

Nomad Foods (NOMD) has been on a downward spiral lately with significant selling pressure. After declining 10.3% over the past four weeks, the stock looks well positioned for a trend reversal as it

Globalstar (GSAT) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.01. This compares to a loss of $0.14 per share a year ago. These figures are adjusted

Kymera KYMR reported a fourth-quarter 2025 loss of 97 cents per share, wider than the Zacks Consensus Estimate of a loss of 77 cents. In the year-ago quarter, Kymera reported a loss of 88 cents per

AutoZone, Inc. AZO is slated to release second-quarter fiscal 2026 results on March 3, before market open. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings per share (EPS) and

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side)

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side)

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side)

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side)

Amneal Pharmaceuticals (AMRX) reported $814.32 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 11.5%. EPS of $0.21 for the same period compares to

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side)

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side)

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm